> Details

Geier, Andreas; Rau, Monika; Pathil-Warth, Anita; von der Ohe, Manfred; Schattenberg, Jörn; Dikopoulos, Nektarios; Stein, Kerstin; Serfert, Yvonne; Berg, Thomas; Buggisch, Peter; Demir, Münevver; Roeb, Elke; Wiebner, Bianka; Wedemeyer, Heiner; Zeuzem, Stefan; Hofmann, Wolf P.

Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry
  • Contributor: Geier, Andreas; Rau, Monika; Pathil-Warth, Anita; von der Ohe, Manfred; Schattenberg, Jörn; Dikopoulos, Nektarios; Stein, Kerstin; Serfert, Yvonne; Berg, Thomas; Buggisch, Peter; Demir, Münevver; Roeb, Elke; Wiebner, Bianka; Wedemeyer, Heiner; Zeuzem, Stefan; Hofmann, Wolf P.
  • imprint: Georg Thieme Verlag KG, 2023
  • Published in: Zeitschrift für Gastroenterologie
  • Language: German
  • DOI: 10.1055/a-1986-7676
  • ISSN: 0044-2771; 1439-7803
  • Keywords: Gastroenterology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p> Background Non-alcoholic fatty liver disease (NAFLD) affects more than 18 million individuals in Germany. Real-world data help to better characterize the natural history of disease and standard of care.</jats:p><jats:p> Methods The German NAFLD-Registry is a prospective non-interventional study initiated by the German Liver Foundation and aims to describe clinical characteristics and observe outcomes in patients with NAFLD recruited in secondary and tertiary care.</jats:p><jats:p> Results From this ongoing study, baseline data of the first 501 patients (mean age 54 years, 48% women) were analysed. 13 % of the study population had a high risk for advanced fibrosis (FIB-4 ≥2.67), approximately one-third had a liver stiffness value ≥9.6kPa measured by transient elastography, and the clinical diagnosis of liver cirrhosis was present in 10%. Typical comorbidities were more prevalent in high risk as compared to low risk patients (FIB-4 &lt;1.3) including arterial hypertension (85 vs. 42%), hypercholesterolemia (39 vs. 16%), and type 2 diabetes mellitus (T2DM) (69 vs. 26%). Patients with T2DM (192/501) had a higher NAFLD disease burden as shown by liver stiffness values ≥9.6 kPa (51%) and clinical diagnosis of cirrhosis (20%). Statins were used in 22% of the main population, while in diabetic patients, metformin, GLP-1 agonists, and SGLT2 inhibitors were used in 65, 17, and 17%, respectively. Uptake of life-style interventions such as physical exercise or nutritional counselling was generally low.</jats:p><jats:p> Conclusion First data of the German NAFLD registry show that approximately every 10th patient has advanced NAFLD, highlights T2DM patients as a high-risk group and gives insights in the use of comedication and life-style interventions in secondary and tertiary care.</jats:p>